Comparison of early F-18 Florbetaben PET/CT to Tc-99m ECD SPECT using voxel, regional, and network analysis

被引：0
作者：
Soo Jin Kwon
Seunggyun Ha
Sang-Won Yoo
Na-Young Shin
Joo Hyun O
Ie Ryung Yoo
Joong-Seok Kim
机构：
[1] The Catholic University of Korea,Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary′s Hospital, College of Medicine
[2] The Catholic University of Korea,Department of Neurology, College of Medicine
[3] The Catholic University of Korea,Department of Radiology, College of Medicine
来源：
Scientific Reports | / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This study aimed to validate early-phase F-18 Florbetaben positron emission tomography (eFBB PET) as a brain perfusion test and determine the optimal reference region. A total of 27 patients with early Parkinson’s disease with Tc-99m ethyl cysteinate dimer single photon emission tomography (ECD SPECT) and FBB PET were included. Six reference regions, including whole brain (GN), pons, central white matter (CWM), whole cerebellum (WC), WC with brain stem (WC + B), and cerebellar grey matter (CG), were applied to obtain SUVR using cortex volume-of-interest (VOI). Reference regions of WC (r 0.886), WC + B (r 0.897), and CG (r 0.904) had highest correlation values of cortex-VOI SUVR between both perfusion images (all p < 0.001). Early-phase FBB PET had a significant linear correlation of CG-normalized SUVR of the cortex, basal ganglia, thalamus, and midbrain with ECD SPECT in voxel-wise analysis (FDR adjusted-p < 0.05). Early-phase FBB PET extracts more ICNS than ECD SPECT, as 9 ICNS and 4 ICNs, respectively. Both eFBB PET and ECD SPECT well discriminated PD from DLB (Area-under-curve of receiver-operating-characteristics, 0.911 for eFBB PET, 0.922 for ECD SPECT). Our findings suggest that eFBB PET is a reliable perfusion test based on a high correlation with ECD SPECT using cerebellum-based normalization methods.
引用
收藏
相关论文
共 40 条
  • [11] Peretti DE(2015)Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 24 197-1670
  • [12] Rodriguez-Vieitez E(2003)(18)F-FDG PET, the early phases and the delivery rate of (18)F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against (15)O-H(2)O PET Neurobiol. Aging 28 1667-1800
  • [13] Tiepolt S(1987)Relative 11C-PiB delivery as a proxy of relative CBF: Quantitative evaluation using single-session 15O-water and 11C-PiB PET J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 58 1791-1745
  • [14] Ottoy J(2002)Staging of brain pathology related to sporadic Parkinson's disease Neurology 57 1740-257
  • [15] Chen YJ(2016)Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 45 249-319
  • [16] Braak H(2009)Phases of A beta-deposition in the human brain and its relevance for the development of AD Neuroimage 55 306-26
  • [17] Kushner M(2004)Cerebellar amyloid-β plaques: How frequent are they, and do they influence 18F-Florbetaben SUV ratios? Ann. Neurol. 43 21-1965
  • [18] Thal DR(2002)Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson's disease J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 55 1959-962
  • [19] Rüb U(2014)Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 40 956-91
  • [20] Orantes M(1999)Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease J. Nucl. Med. 7 9437-235
1234